Pfizer Inc

NYSE: PFE
$26.21
+$0.38 (+1.5%)
Closing Price on November 29, 2024

PFE Articles

Most investors have had a rough 2015, and with the Nasdaq the only index that is up for the year as of Friday, the question is what's the game plan for the rest of the year?
24/7 Wall St. has put together a preview of Apple, Exxon and some of the major Dow Jones Industrial Average companies that are reporting their quarterly results this week.
24/7 Wall St. screened the Merrill Lynch research universe for pharmaceutical stocks paying solid dividends that are rated Buy, and found four outstanding companies.
ThinkstockOctober 21, 2015: Markets opened higher on Wednesday on the trail of gains in both Japan and Europe. Shanghai closed down and the dollar index was lower as well. Crude oil for December...
ThinkstockOctober 20, 2015: Markets opened lower on again on Tuesday as investors trailed along after mixed Asian and European equities markets. In Europe prospects for further central bank easing...
Tuesday's top analyst upgrades, downgrades and initiations include Bluebird Bio, Boston Beer, Etsy, Gilead Sciences, Pfizer, PMC-Sierra and Valeant Pharmaceuticals.
ThinkstockOctober 15, 2015: Markets opened higher on Thursday following a strong showing for stocks in both Asia and Europe. Biotech stocks continue to get new life, helping overcome some softness in...
The bottom line is volatility at higher levels may be here to stay for some time. Owning low-multiple, dividend-paying blue chip leaders makes good sense for long-term growth portfolios.
These Jefferies Franchise picks with solid dividends are perfect for long-term accounts that like to employ a buy-and-hold strategy.
The September 30 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest was mixed.
thinkstockSeptember 28, 2015: Markets opened lower on Monday following a report that personal income rose just 0.3% in August, short of the expected 0.5% economists were looking for. Personal...
The September 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest has increased.
One positive from the hammering the pharmaceutical stocks have taken is the Merrill Lynch analysts say investors have been given a golden opportunity to buy the top companies at much better prices.
The short interest data have been released for the August 31 settlement date, and for the selected pharmaceutical stocks, short interest is mixed.
thinkstockSeptember 10, 2015: Markets opened lower on Thursday after a rather lackluster performance in Asia’s equity markets and more of the same in Europe. Initial claims for unemployment...